本文選題：腹膜透析治療 + 腎功能不全��； 參考：《上海醫(yī)學(xué)》2017年01期

【摘要】：正難治性充血性心力衰竭的發(fā)病率高、病程遷延、預(yù)后差。利尿劑作為治療難治性充血性心力衰竭一線藥物,其作用有限。腹膜透析(PD)治療難治性充血性心力衰竭能夠有效控制容量,糾正電解質(zhì)紊亂,治療腎功能不全和改善心功能。與血液透析(HD)相比,PD治療難治性充血性心力衰竭患者的生存率相同,且無需全身抗凝,血流動(dòng)力學(xué)穩(wěn)定,低血壓發(fā)生風(fēng)險(xiǎn)較小,能夠避免因使用中心靜脈導(dǎo)管(CVC)導(dǎo)致的感染、血栓形成等并
[Abstract]:The incidence of refractory congestive heart failure is high, the course of disease is prolonged and the prognosis is poor. Diuretics as a first-line drug in the treatment of refractory congestive heart failure have limited effect. Peritoneal dialysis (PDD) for refractory congestive heart failure can effectively control volume, correct electrolyte disturbance, treat renal insufficiency and improve cardiac function. The survival rate of patients with refractory congestive heart failure was the same as that of patients with refractory congestive heart failure treated with hemodialysis (HD), without systemic anticoagulation, stable hemodynamics, low risk of hypotension, and the ability to avoid infection caused by the use of central venous catheter (CVC). Thrombosis, etc.
【作者單位】： 交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院腎臟科;
【基金】：上海市衛(wèi)生和計(jì)劃生育委員會(huì)中西醫(yī)結(jié)合重點(diǎn)項(xiàng)目(ZHYY-ZXYJHZX-1-02) 國家自然科學(xué)基金(81573748)資助
【分類號(hào)】：R541.61

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 劉占全;王保暖;趙芬萱;張海松;李繼;;間歇腹膜透析治療糖尿病腎病合并難治性心衰療效分析[J];首都醫(yī)藥;2006年16期

2 張曉桂;于健;;腹膜透析治療尿毒癥并發(fā)心衰的體會(huì)[J];沈陽部隊(duì)醫(yī)藥;1995年04期

3 ;[J];;年期

，

本文編號(hào)：2029964